Abstract
Introduction
Coronary artery disease, the leading cause of mortality and morbidity in the industrialised world, has traditionally been associated with poorer outcomes in patients undergoing aortic valve replacement (AVR) [1] [2] [3] [4] for aortic stenosis. Improvements in surgical technique, myocardial preservation, perioperative management and earlier referral allows concomitant coronary artery bypass grafting (CABG) to be performed in selected patients undergoing AVR, resulting in satisfactory rates of operative mortality and a signifi cant improvement in quality of life compared to medical therapy [1, [5] [6] [7] .
Coronary artery disease and aortic valve disease are two of the most signifi cant contributors to left ventricular (LV) dysfunction [8] . LV dysfunction is associated with poorer outcomes in most cardiac surgical procedures; patients with impaired or severely impaired ejection fraction (EF) have inferior outcomes following isolated AVR or CABG procedures [2, 4, [8] [9] [10] [11] [12] .
Previous work on AVR-CABG suggested LV dysfunction to be a predictor of poorer outcomes following regression analyses [3, 6, 7, 13, 14] . However, these studies did not directly correlate LV dysfunction with operative outcomes in AVR-CABG patients. Two studies assessed small cohorts of patients with LV dysfunction undergoing AVR-CABG and demonstrated inferior post-operative outcomes [2, 9] . However, the multivariate analyses performed were specifi c to isolated AVR, not concomitant surgery. Long-term outcomes for concomitant AVR--CABG surgery were not documented in detail.
Given the paucity of data in this area and the growing recognition of minimally invasive approaches as viable alternatives, we aimed to establish the early and late outcomes in this high-risk population and identify pre-operative risk factors that may facilitate selection and peri-operative optimization [15, 16] .
Methods
All patients undergoing isolated concomitant CABG and AVR between 1 June 2001, and 31 December 2009, at hospitals in Australia participating in the Australian and New Zealand Society of Cardiac and Thoracic Surgeons Cardiac Surgery Database were included in this study. Patients having isolated CABG/valvular surgery or other concurrent cardiac surgical procedures were excluded from this study. A detailed description of data collection and validation methods has been previously provided. The Ethics Committee of each participating hospital had previously approved the use of de-identifi ed patient data contained within the database for research and waived the need for individual patient consent [17, 18] .
In the current study, the preoperative characteristics, early outcomes, and long-term survival of patients with severely impaired (< 30%) and moderately impaired (30-60%) LVEF were compared to those with a normal (> 60%) LVEF.
Fourteen early post-operative outcomes were analyzed. These were: a) 30-day mortality, defi ned as death within 30 days of operation; b) Permanent stroke, defi ned as a new central neurologic defi cit persisting for > 72 h; c) Transient stroke, defi ned as a new transient neurologic defi cit that resolves completely within 72 h (transient ischemic attack or reversible ischemic neurologic defi cit); d) Postoperative acute myocardial infarction, defi ned as at least 2 of the following: enzyme level elevation, new cardiac wall motion abnormalities, or new Q waves on serial electrocardiograms; e) New renal failure, defi ned as at least 2 of the following: serum creatinine increased to more than 200 µmol/L, doubling or greater increase in creatinine vs. preoperative value, or new requirement for dialysis or hemofi ltration; f) Prolonged ventilation (> 24 h); g) Multi-system failure; defined as concurrent failure of 2 or more of the cardiac, respiratory or renal systems for at least 48 h; h) Red blood cell transfusion; i) Gastrointestinal complications; defi ned as post-operative occurrence of any gastrointestinal complication; j) Deep sternal infection involving muscle and bone as demonstrated by surgical exploration and 1 of the following: positive cultures or treatment with antibiotics; k) Return to the operating theatre for any cause; and l) Return to the operating theatre for bleeding.
To assess the impact of LV dysfunction on 30-day mortality, logistic regression was used to adjust for 17 preoperative patient variables, with 30-day mortality as the dependent variable (variables in Table 3 ). Other early outcomes were compared on univariate analysis using the c 2 test. Long-term survival was obtained from the Australian National Death Index, the closing date for which was March 18, 2010. A Kaplan-Meier estimate of survival was obtained and differences in long-term survival were assessed by the log-rank test. The independent impact of LV dysfunction on long-term survival was assessed by constructing a Cox proportional hazards model using EF and other preoperative patient characteristics as variables. Continuous variables are presented as mean ± 1 standard deviation and compared using the unpaired t test and one-way analysis of variance 
Results
Concomitant AVR-CABG surgery was performed in 2,563 patients at 18 Australian institutions; of these, estimated EF was recorded in 2,504. One thousand three hundred and thirty seven (53.7%) patients had a normal EF, 983 (38.3%) had a moderately impaired EF and 144 (5.6%) had a severely impaired EF. Pre-operative and demographic characteristics of patients, stratifi ed by EF are provided in Table 1 . There were some notable differences in intra-operative variables between the three groups ( Table 2) .
Overall 30-day mortality and in-hospital mortality were 3.8% and 4.2%, respectively. The unadjusted 30-day mortality rate was 2.9% in patients with normal EF, 4.3% in patients with impaired EF and 9.0% in patients with severely impaired EF. This difference was signifi cant on univariate analysis (p = 0.001). Logistic regression (Table 3) showed that impaired EF and severely impaired EF were not predictors of 30-day mortality on multivariate analysis. Patients with severely impaired and impaired EF had a signifi cantly higher mean post-operative length of stay (14.69 ± 12.38 vs. 12.32 ± 11.07 vs. 11.16 ± 10.27, p < 0.001) and intensive care unit stay (113.75 ± 159.67 vs. 68.64 ± 104.30 vs. 61.11 ± 108.47 h, p < 0.001) compared to patients who had normal EF ( Table 4) .
The mean follow-up was 36 months (range 0-106). Long-term survival at 3 and 5 years was signifi cantly lower on multivariate analysis in patients with severely impaired EF (p = 0.02), but not in those with impaired EF (p = 0.247) (88.4% vs. 84.1% vs. 69.2%, 82.5% vs. 77.1% vs. 63.7%) compared to those with normal EF (Fig. 1) . A Cox regression model predicting late mortality is shown in Table 5 . 
Discussion
Chronic aortic valve stenosis leads to the development of compensatory mechanisms, which promote LV hypertrophy to maintain cardiac output [12, 13] . Over time, these mechanisms fail and the resulting ventricular dilatation leads to increasing myocardial oxygen consumption and further decline in systolic function [12, 13, 19] . Most patients Patients with severe LV dysfunction were found to have worse early outcomes. Our results demonstrated an unadjusted 30-day mortality rate of 9.0% compared with 4.3% and 2.9% in patients with moderately impaired and normal ventricular function, respectively. This was significant on univariate but not on multi-variate analysis. The NYHA classifi cation, traditionally only a subjective assessment of the degree of LV dysfunction, age and cerebrovascular disease was found to be an independent predictor of early mortality in our study [20] . Similarly, Chikwe et al. [2] demonstrated an 8% mortality rate in patients with EF < 30% and severe aortic stenosis with low transvalvular gradients who underwent AVR-CABG, compared to a 2% mortality rate in patients with normal EF with no signifi cant difference. In our study, the cohort with severely impaired LVEF experience with greater post-operative complications that included new renal failure, pneumonia, multi-system failure and prolonged ventilation; which is consistent with the study by Chikwe et al. [2] . It is well known that LV dysfunction may compound other co-morbidities, which may then further contribute to early mortality [9, 10, 12] . Modern myocardial protection strategies and improved perioperative care has stymied the adverse effects of prolonged ischemia during concomitant surgery with an in--hospital mortality of around 10% being achievable in experienced centers, compared with 20% a few decades ago [2] . Peri-operative management of LV dysfunction and other concurrent comorbidities is paramount in order to optimize surgical outcomes in this high-risk group.
Long-term outcomes were signifi cantly worse in patients with severely impaired LV function and LV dysfunction was a predictor of inferior outcomes on multi-variate analysis. Our results are consistent with the existing literature. Kobayashi et al. [7] found survival in patients undergoing com- [9] demonstrated that the 5-year survival of AVR/CABG was 62% for EF less than 40%. Given the high pre-operative risk and poorer long-term outcomes, previous studies have advocated for a more cautious approach towards patient selection in those with advanced LV failure. However, this must be considered in the context of the poor natural history of aortic stenosis with previous reports suggesting that patients have a life expectancy of only 2 years [12] . The increased operative risk must be balanced with the potential gain in both length and quality of life. Age is ultimately a signifi cant factor that determines suitability for operative action, with several studies (including ours) demonstrating the detrimental effects of increasing age on short-and long-term outcomes following cardiac surgery [21, 22] . Patients with impaired LVEF presented with concurrent medical problems; several of these were demonstrated to predict long-term survival. Thus a rigorous pre-operative work-up and medical optimization should be performed, considering the person's age, ventricular function and other comorbidities in order to encompass the widest cohort of patients who will benefi t from surgery. Future work looking at the effects of concomitant surgery in octogenarians with severely impaired LV dysfunction may be useful to identify if this cohort is a relative contraindication to surgery. Indications for either a concomitant approach or an isolated approach for the dominant pathology are widely debated in the context of LV dysfunction. It is known that the combined approach portends an increased operative risk; our results refl ect this trend [15, 23] . Proponents of the combined approach argue that this population would avoid a second major procedure, and that subsequent regression in LV mass and improvement in EF confers upon them increased life expectancy and quality, and decreased re-intervention rates, which would not have been afforded had surgery not been performed [13, 19, 23, 24] . Opponents argue that the progression of the secondary pathology is slow and does not necessitate immediate action. Subsequent surgical intervention may be performed without additional risk. In valve replacement surgery for incidental aortic valve pathology, for instance, patients are unnecessarily exposed to additional risk factors associated with the operation, and subsequently require lifetime anti-coagulation [13, 19, 23] . Several studies, however, have shown that progression of asymptomatic aortic stenosis at the time of CABG to a state which requires an AVR averages between 4 and 9 years depending on the underlying pathology [13] . The additional risk of AVR-CABG in patients with LVEF is only slight, compared to patients with compromised LVEF undergoing single procedures; our results refl ect this trend. Given the natural history of aortic valve and coronary vessel disease, with its deleterious effects on ventricular function, concomitant 'prophylactic' AVR-CABG in patients with normal to impaired LV dysfunction for varying severities of aortic stenosis at the time of CABG may be performed without additional risk [13] . This may avoid re-intervention after initial surgery to correct the secondary pathology, which may have progressed to cause impaired or severely impaired ventricular function; this subjects patients to a riskier operation, which could have been avoided if they had undergone a concomitant procedure [13, 19, 24] . For patients with severely impaired LVEF, we have shown comparable short-term outcomes and long term survival compared to studies analyzing single procedures in the context of severely impaired LVEF. For isolated AVR in patients with poor LV function, Halkos et al. [9] showed that patients with an EF between 25% and 40% had an in-hospital mortality of 14.5% and a 5-year survival of 62%. A systematic review by Kunadian et al. [8] demonstrated an operative mortality of 5.4% and a 5-year survival of 73.4% in patients with a mean EF of 24.7% in patients undergoing isolated CABG. These results are similar to ours, which suggest that AVR--CABG may be performed safely in this population.
The poor prognosis of patients with LV dysfunction requiring concomitant surgery has led to several arguments being mooted in the literature supporting percutaneous intervention techniques. This mainly involves trans-apical or trans-femoral aortic valve implantation followed by percutaneous coronary intervention, both of which carry a signifi cantly lower peri-operative risk and mortality in this subset of patients [15, 16] . In patients seen to have a signifi cant peri-operative risk with uncontrolled comorbidities, this may present itself as a viable option [25] . However, it should not be seen at this stage to be a panacea for patients with LV dysfunction requiring concomitant surgery. Studies continue to suggest that CABG achieves superior outcomes to percutaneous coronary intervention in patients with left main or triple vessel disease, especially those with diabetes [26, 27] . Moreover, conventional AVR is regarded as the gold standard in the management of severe symptomatic aortic stenosis although promising outcomes have been reported for transcatheter AVR more recently [28, 29] . Randomized studies, despite their logistic limitations are needed further investigate the effi cacy of hybrid transcatheter valve and percutaneous revascularization procedures.
Out study is the largest multi-centre study of patients undergoing concomitant AVR-CABG. The data presented here was subjected to both local validation and external auditing. Hence, the level of accuracy of the reported pre-, intra-and post--operative variables, along with the operative complications and mortality rates, is high. How ever, it was subject to the usual caveats of retrospective work. Firstly, selection bias and confounding from unknown variables is likely to be present. Our dataset lacks information on drug medication preoperatively, at discharge and during follow-up. Patient characteristics were heterogeneous throughout, which may have introduced various bias and confounders to the results. Other long-term clinical endpoints which included re-occurrence of angina or need for further re-intervention were not available, which would have been useful to measure.
Conclusions
Our results demonstrate that combined CABG/ /AVR can be performed in this challenging subgroup of patients with results similar to isolated AVR replacement with severe LV dysfunction. Given the limitations of drawing concrete conclusions from retrospective work, patients should not be denied surgery based on their LV dysfunction alone. Rather, an individualized approach should be championed, with due consideration of all patient factors.
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